IL102778A - Controlled-release preparations with a spheroidal nucleus and a process for their preparation - Google Patents

Controlled-release preparations with a spheroidal nucleus and a process for their preparation

Info

Publication number
IL102778A
IL102778A IL10277892A IL10277892A IL102778A IL 102778 A IL102778 A IL 102778A IL 10277892 A IL10277892 A IL 10277892A IL 10277892 A IL10277892 A IL 10277892A IL 102778 A IL102778 A IL 102778A
Authority
IL
Israel
Prior art keywords
controlled release
composition according
cores
spheroid
spheroid cores
Prior art date
Application number
IL10277892A
Other languages
English (en)
Hebrew (he)
Other versions
IL102778A0 (en
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919117361A external-priority patent/GB9117361D0/en
Priority claimed from GB919122967A external-priority patent/GB9122967D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of IL102778A0 publication Critical patent/IL102778A0/xx
Publication of IL102778A publication Critical patent/IL102778A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Fertilizers (AREA)
IL10277892A 1991-08-12 1992-08-10 Controlled-release preparations with a spheroidal nucleus and a process for their preparation IL102778A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919117361A GB9117361D0 (en) 1991-08-12 1991-08-12 Oral dosage form
GB919122967A GB9122967D0 (en) 1991-10-29 1991-10-29 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
IL102778A0 IL102778A0 (en) 1993-01-31
IL102778A true IL102778A (en) 1999-05-09

Family

ID=26299395

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10277892A IL102778A (en) 1991-08-12 1992-08-10 Controlled-release preparations with a spheroidal nucleus and a process for their preparation

Country Status (14)

Country Link
US (2) US5670172A (es)
EP (1) EP0527637B1 (es)
JP (1) JP3019235B2 (es)
KR (1) KR100221695B1 (es)
CN (1) CN1052398C (es)
AT (1) ATE165513T1 (es)
AU (1) AU651715B2 (es)
CA (1) CA2075356A1 (es)
DE (1) DE69225278D1 (es)
ES (1) ES2115643T3 (es)
FI (1) FI923582A (es)
IL (1) IL102778A (es)
NO (1) NO304406B1 (es)
PH (1) PH31288A (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
AU9221898A (en) * 1997-09-09 1999-03-29 Alza Corporation Pharmaceutical coating composition and method of use
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
DK1685839T3 (da) * 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
KR100417490B1 (ko) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
PT1178952E (pt) 1999-05-14 2007-12-04 Univ California Novos moduladores da interleucina-1 e do factor alfa de necrose tumoral, síntese dos referidos moduladores e métodos de utilização dos referidos moduladores
GB9913979D0 (en) 1999-06-17 1999-08-18 Univ Wales Medicine Spheroid preparation
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US20040171107A1 (en) * 2000-02-23 2004-09-02 David Nelson Modified flourescent proteins
US6852031B1 (en) * 2000-11-22 2005-02-08 Igt EZ pay smart card and tickets system
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
EP1341414B1 (en) * 2000-11-16 2013-01-02 The Regents of The University of California Marine actinomycete taxon for drug and fermentation product discovery
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
RU2004106619A (ru) 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
EP2308475A1 (en) 2002-04-05 2011-04-13 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
AU2003296908A1 (en) * 2002-09-27 2004-05-04 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20040208932A1 (en) * 2003-04-17 2004-10-21 Ramachandran Thembalath Stabilized paroxetine hydrochloride formulation
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
BRPI0411677A (pt) * 2003-06-20 2006-08-29 Nereus Pharmaceuticals Inc métodos de uso de compostos heterocìclicos [3.2.0] e seus análogos
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
DE602004025592D1 (de) * 2003-09-12 2010-04-01 Life Technologies Corp Anwendungen des Resonanzenergietransfers zwischen Terbium und GFP
CA2552350A1 (en) * 2004-01-23 2005-08-04 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
EP2025679A3 (en) 2004-04-30 2009-07-08 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
BRPI0518483A2 (pt) 2004-11-23 2008-11-18 Neuromolecular Pharmaceuticals Inc composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
SG157365A1 (en) 2004-12-03 2009-12-29 Dana Farber Cancer Inst Inc Compositions and methods for treating neoplastic diseases
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
AU2006228536A1 (en) * 2005-03-31 2006-10-05 Rafael Armament Development Authority Ltd. Spherically shaped substances
CA2604052C (en) * 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
JP2009505954A (ja) 2005-07-21 2009-02-12 ネレアス ファーマシューティカルズ インコーポレイテッド インターロイキン−１及び腫瘍壊死因子−ａ修飾因子、このような修飾因子の合成及びこのような修飾因子の使用方法
PL2034975T3 (pl) 2006-06-19 2012-09-28 Alpharma Pharmaceuticals Llc Kompozycje farmaceutyczne
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
CA2709992A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Abuse resistant pharmaceutical compositions of opiod agonists
CA2707980C (en) * 2007-12-17 2015-05-12 Labopharm Inc. Misuse preventative, controlled release formulation
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2723465A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
NZ590952A (en) * 2008-07-07 2012-09-28 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
CN102883601A (zh) 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
JP2014516080A (ja) * 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
ITFI20110172A1 (it) * 2011-08-08 2013-02-09 Valpharma Sa Formulazione multiparticolata a rilascio modificato di diltiazem hcl.
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
MX2016000810A (es) 2013-07-23 2016-08-05 Euro Celtique Sa Combinacion de oxicodona y naloxona para su uso en el tratamiento de dolor en pacientes que sufren de dolor y una enfermedad que resulta la disbiosis intestinal y/o aumento del riesgo de la translocacion bacteriana intestinal.
EP3189007B1 (en) 2014-09-02 2019-10-02 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
CA2963923A1 (en) 2014-10-08 2016-04-14 Pacific Northwest Research Institute Methods and compounds for increasing the potency of antifungal agents
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CN112533614A (zh) 2018-03-28 2021-03-19 美国康宝莱国际公司 多糖的乙酰化

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456628A (en) * 1981-01-07 1984-06-26 Bauer Kurt H Process for film-coating a particulate solid, and emulsions for conducting the process
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
US4643731A (en) * 1985-08-16 1987-02-17 Alza Corporation Means for providing instant agent from agent dispensing system
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
DE3709188A1 (de) * 1987-03-20 1988-09-29 Mannesmann Ag Ausgiessrohr fuer metallurgische gefaesse
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
BE1000794A4 (nl) * 1987-07-30 1989-04-04 Schelde Delta Bv Met Beperkte Werkwijze voor het bij chemische processen immobiliseren van komponenten in een fluidumstroom, en inrichtingen die deze werkwijze toepassen.
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US5219621A (en) * 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
ATE241987T1 (de) * 1987-10-16 2003-06-15 Elan Corp Plc Diltiazem-zusammensetzungen mit kontrollierter wirkstoffabsorption
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
FR2623714B1 (fr) * 1987-11-26 1990-04-20 Ethypharm Sa Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
GB8805695D0 (en) * 1988-03-10 1988-04-07 Nycomed As Enteric coated spheroidal granules
FI101344B (fi) * 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
FR2630647B1 (fr) * 1988-04-27 1991-08-16 Sanofi Sa Microbilles de diltiazem, leur procede de fabrication et compositions pharmaceutiques a liberation prolongee les contenant
IL92484A0 (en) * 1988-11-30 1990-08-31 Schering Corp Sustained release diltiazem formulation
SE506179C2 (sv) * 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation

Also Published As

Publication number Publication date
IL102778A0 (en) 1993-01-31
NO923128L (no) 1993-02-15
NO304406B1 (no) 1998-12-14
EP0527637B1 (en) 1998-04-29
ES2115643T3 (es) 1998-07-01
CA2075356A1 (en) 1993-02-13
AU2088092A (en) 1993-02-18
US5670172A (en) 1997-09-23
ATE165513T1 (de) 1998-05-15
EP0527637A1 (en) 1993-02-17
PH31288A (en) 1998-07-06
US5601845A (en) 1997-02-11
KR100221695B1 (ko) 1999-09-15
AU651715B2 (en) 1994-07-28
CN1069408A (zh) 1993-03-03
DE69225278D1 (de) 1998-06-04
FI923582A (fi) 1993-02-13
FI923582A0 (fi) 1992-08-11
KR930003906A (ko) 1993-03-22
NO923128D0 (no) 1992-08-11
JP3019235B2 (ja) 2000-03-13
CN1052398C (zh) 2000-05-17
JPH05201867A (ja) 1993-08-10

Similar Documents

Publication Publication Date Title
AU651715B2 (en) Pharmaceutical spheroid formulation
US5508044A (en) Diltiazem pharmaceutical spheroid formulation
US9814684B2 (en) Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US6153220A (en) Taste-masked formulations
US5489439A (en) Granular pharmaceutical formulations
ES2255521T3 (es) Revestimiento.
EP0213083A2 (en) Controlled release tablet
BR112012025015B1 (pt) Formulações farmacêuticas para tratamento de bexiga hiperativa.
SE509029C2 (sv) Långtidsverkande diklofenak-natriumpreparat
HU204201B (en) Coating materialdetermining delivery of active components from pharmaceutical compositions, and process for producing phrmaceutical compositions containing this coating material
EP0211991B1 (en) Substained release tablets and method for preparation thereof
US20130216617A1 (en) Pharmaceutical compositions of (r)-lansoprazole
SK278868B6 (sk) Prípravok s retardovaným uvoľňovaním účinnej látky
US5344657A (en) Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them
FI100303B (fi) Menetelmä suun kautta annettavan buspironin ja sen suolan valmistamise ksi
AU1543702A (en) Multiparticulate formulations of lithium salts for oral administration suitable for-a-day administration
GB2258613A (en) Pharmaceutical diltiazem spheroid formulation
SK282303B6 (sk) Spôsob výroby liekovej formy obsahujúcej karbamazepín s oneskoreným uvoľňovaním účinnej látky
WO2021111419A1 (en) Modified release pharmaceutical compositions of riociguat
GB2258810A (en) Pharmaceutical combination formulation of diltiazem and hydrochlorothiazide

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired